Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Regeneron (REGN) Resumes Trading Up 1%
June 9, 2015 6:50 PM EDTRegeneron (NASDAQ: REGN) resumed trading up 1% after confirming FDA panel backing of Praluent injection.
... MoreRegeneron (REGN) to Resume Trading at 6:50PM ET
June 9, 2015 6:36 PM EDTRegeneron (NASDAQ: REGN) is set to resume trading at 6:50PM ET after confirming FDA panel backing of Praluent.
... MoreRegeneron (REGN) Confirms FDA Panel Backing of Praluent
June 9, 2015 6:34 PM EDTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) confirmed that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the investigational therapy Praluent® (alirocumab) Injection.
The Committee voted 13 to three (with no abstentions) that Regeneron and Sanofi had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
"We are pleased with the Committee's recommendation to approve Praluent. Our clinical trial program... More
Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital Says
June 8, 2015 7:03 AM EDTBMO Capital analyst Jim Birchenough reiterated his Market Perform rating and $381 price target on Regeneron Pharma (NASDAQ: REGN) following briefing document last Friday for the June 9 Advisory Committee meeting on REGN/Sanofi's PRALUENT. Birchenough said while the document appears to be highly positive on PRALUENTs efficacy in LDL-C lowering and safety profile, the analyst notes risk to labeling for statin... More
FDA Breifing Documents for Regeneron's (REGN) Praluent 'Read Well,' Says RBC Capital
June 5, 2015 9:35 AM EDTRBC Capital maintained an Outperform on Regeneron Pharma (NASDAQ: REGN). Earlier the FDA posted briefing docs for Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK-9 drug Praluent. In the view of analyst Adnan Butt, FDA documents "read well."
"Overall conclusions... More
